Conclusion
This report introduces the potentially beneficial effects of infliximab
in the treatment of COVID-19 patients. Inhibition of TNF-α via
infliximab may reduce the COVID-19 disease progression. The ventilator
may increase complications in the COVID-19 patient, so TNF-α inhibition
should occur before the ventilator’s use. Large randomized study samples
are necessary to investigate the efficacy of infliximab, and
combinations with other immunomodulating drugs like Anakinra or
chemokine inhibitors may reveal new treatment guidelines for COVID-19
patients.